New York Times Criticized for Promoting Questionable AI Startup Selling GLP-1 Drugs
The article criticizes the New York Times for publishing a positive article about an AI startup, Medvi, that is allegedly selling GLP-1 drugs through dubious means, including fake doctors, phony before-and-after pictures, and a warning from the FDA.
Why it matters
This news highlights concerns about the lack of scrutiny and oversight in the AI industry, where startups may be able to mislead the public and regulators through deceptive marketing tactics.
Key Points
- 1Medvi is an AI startup selling GLP-1 drugs online
- 2The company is accused of using fake doctors and phony before-and-after photos
- 3The FDA has issued a warning about Medvi's practices
- 4The New York Times is criticized for publishing a positive article about Medvi
Details
The article criticizes the New York Times for publishing a positive article about an AI startup called Medvi, which is allegedly selling GLP-1 drugs (a type of diabetes medication) through questionable means. The article claims that Medvi is using fake doctors, phony before-and-after pictures, and other deceptive tactics to sell its products. The FDA has also issued a warning about Medvi's practices. The author argues that the New York Times article is essentially 'laundering the reputation' of this sleazy AI startup, despite the numerous red flags surrounding its operations.
No comments yet
Be the first to comment